Demant A/S/DKr DEMANT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Demant A/S
Demant A/S is a Danish company that operates in the healthcare industry, primarily focusing on hearing health. The company designs, develops, and manufactures hearing aids, audiometric equipment, and personal communication devices. Established in 1904, Demant has grown to become a globally recognized player in the hearing healthcare sector. Headquartered in Smørum, Denmark, Demant's products and services are available worldwide through a network of subsidiaries and distributors. The company is noted for integrating advanced technology into its offerings, allowing for improved user experiences and health outcomes. Its strategic position is strengthened by a continuous focus on innovation and a comprehensive product portfolio that caters to various aspects of hearing health.
- Ticker
- DKr DEMANT
- Sector
- Health
- Primary listing
- CSE
- Employees
- 26,616
- Headquarters
- Smørum, Denmark
- Website
- www.demant.com
Demant A/S Metrics
BasicAdvanced
kr 76B
47.06
kr 7.64
0.76
-
Price and volume
Market cap
kr 76B
Beta
0.76
52-week high
kr 364.00
52-week low
kr 175.00
Average daily volume
304K
Financial strength
Current ratio
0.821
Quick ratio
0.531
Long term debt to equity
1.16
Total debt to equity
1.792
Interest coverage (TTM)
7.82%
Profitability
EBITDA (TTM)
4,972
Gross margin (TTM)
76.25%
Net profit margin (TTM)
6.55%
Operating margin (TTM)
17.20%
Effective tax rate (TTM)
23.76%
Revenue per employee (TTM)
kr 930,000
Management effectiveness
Return on assets (TTM)
7.29%
Return on equity (TTM)
23.30%
Valuation
Price to earnings (TTM)
47.061
Price to revenue (TTM)
3.081
Price to book
6.74
Price to tangible book (TTM)
-8.03
Price to free cash flow (TTM)
24.45
Free cash flow yield (TTM)
4.09%
Free cash flow per share (TTM)
14.707
Growth
Revenue change (TTM)
9.06%
Earnings per share change (TTM)
-29.26%
3-year revenue growth (CAGR)
5.62%
10-year revenue growth (CAGR)
7.98%
3-year earnings per share growth (CAGR)
1.92%
10-year earnings per share growth (CAGR)
3.98%
What the Analysts think about Demant A/S
Analyst ratings (Buy, Hold, Sell) for Demant A/S stock.
Analyst projections of the future price of Demant A/S stock.
Bulls say / Bears say
After Q3 organic growth of 11%, Demant raised 2026 guidance to 7–8% organic growth and DKK 4.7–5.0bn EBIT before special items, signalling stronger-than-expected trading. (MarketScreener)
Oticon Reveal’s launch is translating innovation into demand: Demant said it drove Q3 growth, following 9% first-half organic growth in Hearing Aids led by Zeal and estimated market-share gains above the market. (MarketScreener, Demant A/S)
Demant resumed share buy-backs and plans to repurchase at least DKK 3bn by the end of 2027, citing strong cash flow and confidence in reaching its leverage target. (MarketScreener)
The outlook still faces a crowded product cycle: Demant said several competitors were expected to launch products in the second half, putting its market-share gains under pressure. (Demant A/S)
KIND was debt-funded; at H1, net interest-bearing debt was DKK 17.95bn and gearing was 3.0x, above Demant’s 2.0–2.5x long-term target, leaving the balance sheet exposed while integration continues. (Demant A/S)
Integration and restructuring carry a material near-term cost: Demant raised 2026 special items to DKK 400m and expects a further DKK 100m in 2027, weighing on reported earnings. (Demant A/S)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2026.
Demant A/S Financial Performance
Revenues and expenses
Demant A/S Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Demant A/S
AllEURUSDGBP
Fund name | Fund size | DKr DEMANT weighting |
|---|---|---|
Xtrackers MSCI Nordic£XDN0 | €1.1B | 0.31% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 0.24% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 0.24% |
iShares MSCI Europe Health Care Sector£ESIH | €890M | 0.24% |
Invesco MSCI World Equal Weight£MWEP | $2B | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.